

UK Cystic Fibrosis Infection Biorepository (UKCFIB) Enquiry Form

Please complete and return this form via email to UKCFIB Coordinator. We will use the information you share to identify how the biorepository can best support your research and aim to be in touch within one week of receipt.

Please do not include confidential information on this form.

| Section 1: About You | |
|----------------------|--|
| Name | |
| Affiliation | |
| Address | |
| Email | |

| Section 2: About Your Research Project | |
|---|--|
| Project Background and Summary | |
| Expected value of the research to CF or other chronic respiratory diseases | |
| Intended dissemination of project results including anticipated publications. | |

| Section 3: About the samples, data and capability you would like to access | |
|--|--|
| Bacterial clinical isolates required | |
| Other sample types required | |
| Are there any aspects of your project that you would value additional support for (e.g. screening, guidance) or anything else not captured | |

MATERIAL TRANSFER AGREEMENT & COST RECOVERY

MATERIAL TRANSFER AGREEMENT

To enable more efficient processing of sample requests an overarching MTA has been developed to cover requests for a basic set of pathogens. The MTA also covers data sharing and includes a proposed user fee model to aid cost recovery as part of UKCFIB's sustainability plan. Participating centres will retain ownership of samples/data and make access decisions.

The majority of centres have Material Transfer Agreements (MTA) and Laboratory Service Agreements (LSA) in place to enable the sharing of samples and data with third parties. There are no restrictions on transferring reference strains and clinical isolates to third parties but in the case of sputum collections, ethical consents do not typically allow transfer of samples to third parties. In such cases, individual centres have agreed a willingness to take on experimentation at their local site to a mutual agreement including with respect to IP and in accordance with approved ethics.

- **Sample types covered by standard MTA:**
The standard MTA will cover currently existing collections of reference strains and clinical isolates.
- **Sample types not covered by the MTA:**
The MTA is not valid for sputum nor requests for prospective samples and data.

Acknowledgements of source of samples

The Recipient must acknowledge the contribution of the Provider and the source of the Materials in any publication or report that may result from use of the Materials. The UK Cystic Fibrosis Infection Biorepository should be acknowledged in the following manner: **"Clinical isolates were supplied by 'insert relevant institute/centre', which is part of the UK Cystic Fibrosis Infection Biorepository"**.

I. COST RECOVERY

To help cover a proportion of the administrative running costs of centres in the network and as part of the biorepository's sustainability plan, the following user fees and conditions will be applied. The user fees will apply to currently existing collections of reference strains and clinical isolates. The user fees are not valid for sputum nor prospective samples and data. Proposed fees are aligned with charges applied by BCCM.

Commercial entities: £105 per isolate
Conditions: Retains full ownership of IP

Non-commercial entities: £75 per isolate
Conditions: Share IP, co-authorship

Payments will be managed independently of the UK CF Infection biorepository.

Individual centres can reserve the right to change these costs dependent on specific request.

